Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma.

Literature DB >> 25999447

Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma.

Chan Yoon Cheah¹, Loretta J Nastoupil¹, Sattva S Neelapu¹, Sheryl G Forbes¹, Yasuhiro Oki¹, Nathan H Fowler¹.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2015 PMID： 25999447 PMCID： PMC5161005 DOI： 10.1182/blood-2015-03-633156

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

× No keyword cloud information.

4 in total

Review 1. PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances.

Authors: Lomon So; David A Fruman
Journal: Biochem J Date: 2012-03-15 Impact factor: 3.857

2. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

Authors: Richard R Furman; Jeff P Sharman; Steven E Coutre; Bruce D Cheson; John M Pagel; Peter Hillmen; Jacqueline C Barrientos; Andrew D Zelenetz; Thomas J Kipps; Ian Flinn; Paolo Ghia; Herbert Eradat; Thomas Ervin; Nicole Lamanna; Bertrand Coiffier; Andrew R Pettitt; Shuo Ma; Stephan Stilgenbauer; Paula Cramer; Maria Aiello; Dave M Johnson; Langdon L Miller; Daniel Li; Thomas M Jahn; Roger D Dansey; Michael Hallek; Susan M O'Brien
Journal: N Engl J Med Date: 2014-01-22 Impact factor: 91.245

3. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

Authors: Ajay K Gopal; Brad S Kahl; Sven de Vos; Nina D Wagner-Johnston; Stephen J Schuster; Wojciech J Jurczak; Ian W Flinn; Christopher R Flowers; Peter Martin; Andreas Viardot; Kristie A Blum; Andre H Goy; Andrew J Davies; Pier Luigi Zinzani; Martin Dreyling; Dave Johnson; Langdon L Miller; Leanne Holes; Daniel Li; Roger D Dansey; Wayne R Godfrey; Gilles A Salles
Journal: N Engl J Med Date: 2014-01-22 Impact factor: 91.245

Review 4. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.

Authors: H Quach; D Ritchie; A K Stewart; P Neeson; S Harrison; M J Smyth; H M Prince
Journal: Leukemia Date: 2009-11-12 Impact factor: 11.528

4 in total

37 in total

Review 1. Novel immunotherapy approaches to follicular lymphoma.

Authors: Christopher R Flowers; John P Leonard; Loretta J Nastoupil
Journal: Hematology Am Soc Hematol Educ Program Date: 2018-11-30

Review 2. The PI3K Pathway in Human Disease.

Authors: David A Fruman; Honyin Chiu; Benjamin D Hopkins; Shubha Bagrodia; Lewis C Cantley; Robert T Abraham
Journal: Cell Date: 2017-08-10 Impact factor: 41.582

Review 3. Frontline strategy for follicular lymphoma: are we ready to abandon chemotherapy?

Authors: Nathan Fowler
Journal: Hematology Am Soc Hematol Educ Program Date: 2016-12-02

Review 4. Novel agents in follicular lymphoma: choosing the best target.

Authors: Laurie H Sehn
Journal: Hematology Am Soc Hematol Educ Program Date: 2016-12-02

Review 5. Current challenges in the management of follicular lymphoma.

Authors: Maryam Sarraf Yazdy; Chaitra Ujjani
Journal: Int J Hematol Oncol Date: 2017-06-30

6. Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia.

Authors: Candida Vitale; Alessandra Ferrajoli
Journal: Haematologica Date: 2019-01 Impact factor: 9.941

7. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.

Authors: Sonali M Smith; Brandelyn N Pitcher; Sin-Ho Jung; Nancy L Bartlett; Nina Wagner-Johnston; Steven I Park; Kristy L Richards; Amanda F Cashen; Anthony Jaslowski; Scott E Smith; Bruce D Cheson; Eric Hsi; John P Leonard
Journal: Lancet Haematol Date: 2017-03-15 Impact factor: 18.959